Showing results (4351-4360 of 6,740) with videos related to

Sort By:
Pageof 674
Oncotargets and Therapy|December 5, 2014
FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotypingChien-Yu Lu, Yung-Sung Yeh, Ching-Wen Huang, et al.
Oncotargets and Therapy|December 5, 2014
Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of ChinaFang-Jing Ma, Zhe-Bin Liu, Li Qu, et al.
Oncotargets and Therapy|December 5, 2014
Cytologic surveillance versus immediate colposcopy for women with a cervical smear diagnosis of low-grade squamous intraepithelial lesion in a poor setting in NigeriaLo Ajah, Co Chigbu, He Onah, et al.
Oncotargets and Therapy|November 28, 2014
Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinomaDeng Cai, Hang Li, Rui Wang, et al.
Oncotargets and Therapy|November 25, 2014
Elevation of methylated DNA in KILLIN/PTEN in the plasma of patients with thyroid and/or breast cancerEnders K Ng, Vivian Y Shin, Candy P Leung, et al.
Oncotargets and Therapy|November 25, 2014
Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphomaAntonio Gutierrez, Jose Rodriguez, Jordi Martinez-Serra, et al.
Oncotargets and Therapy|November 25, 2014
Natural history of histologically moderate cervical dysplasia in adolescent and young womenSalvador Piris, Victoria Bravo, Carmen Alvarez, et al.
Oncotargets and Therapy|November 4, 2014
Inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cell linesYing Qian, Yanning Liu, Qiuyue Yan, et al.
Oncotargets and Therapy|November 18, 2020
Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell TransplantQing Li, Juan Mu, Jijun Yuan, et al.
Oncotargets and Therapy|November 18, 2020
A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung AdenocarcinomaShaowei Lan, Hui Li, Ying Liu, et al.
Pageof 674